RECURRENT PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for RECURRENT PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo trial offers hope for Tough-to-Treat ovarian cancer
Disease control OngoingThis study aims to find the best drug combination to control recurrent ovarian cancer that has stopped responding to standard platinum-based chemotherapy. It is testing a chemotherapy drug (pegylated liposomal doxorubicin) alone or combined with one or two immunotherapy drugs (at…
Matched conditions: RECURRENT PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Can an Immune-Boosting drug help a cancer pill fight ovarian cancer better?
Disease control OngoingThis study is testing if a combination of two drugs works better than one alone to control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It compares a standard targeted drug (olaparib) against that same drug plus an immunotherapy drug (tremelimumab). The main g…
Matched conditions: RECURRENT PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New hope for tough ovarian cancers: Triple-Drug attack tested
Disease control OngoingThis study is testing whether combining two or three newer drugs works better than standard chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to platinum-based drugs. It will involve about 120 women who have alr…
Matched conditions: RECURRENT PRIMARY PERITONEAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 02, 2026 15:22 UTC